- PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS
-
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.
- -
-
Page/Page column 78; 82; 159
(2021/04/10)
-
- HETEROCYCLIC COMPOUND
-
The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
- -
-
Paragraph 0676
(2015/01/18)
-
- SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN
-
Disclosed herein are small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and pro-drugs and pharmaceutically acceptable salts thereof. The Also featured are pharmaceutical compositions of the compounds and uses of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, and neuropathic pain)
- -
-
-
- Facile cyanomethylation of bromopyridines by nucleophilic substitution with lithioacetonitrile
-
Substituted bromopyridines undergo facile nucleophilic substitution with lithioacetonitrile under mild conditions to afford the corresponding cyanomethylated products.
- Skerlj,Bogucki,Bridger
-
p. 1488 - 1490
(2007/10/03)
-
